| Autor: |
Jorgetti, V., Ricco Soeiro, N. M., Mendes, V., Pereira, R. C., Crivellari, M. E., Coutris, G., Borelli, A., Ribeiro Leite, M. O., Nussenzweig, I., Marcondes, M., Drüeke, T., Cournot, G. |
| Zdroj: |
Nephrology Dialysis Transplantation; Jun1994, Vol. 9 Issue 6, p668-674, 7p |
| Abstrakt: |
We investigated (1) the prevalence of aluminium overload among 96 patients with symptomatic bone disease haemodialysed from 1987 to 1989 in the Sao Paulo area, Brazil; (2) the effect of 6 months desferrioxamine (DFO) treatment (1–2 g/week). All patients underwent a first bone biopsy. Aluminium overload (extent of stainable bone aluminium more than 20% trabecular surface) was observed in 74 of 96 patients. Forty overloaded patients were divided into patients with high bone formation rate (BFR) (group 1; =17) and patients with low BFR (group 2; =23), and had a second biopsy after DFO therapy. In both groups aluminium surface was reduced after treatment (<0.001), osteoblast surface (<0.02-<0.01) and plasma parathyroid hormone (iPTH) (<0.01) increased. In group 1 BFR remained high. In group 2 BFR remained low in 16 patients (2a) and increased in seven (<0.02) (2b). In group 2a plasma phosphorus was below that in group 2b patients, before (<0.03) and after (<0.01) DFO. The histological features of group 2a patients resembled hypophos-phataemic osteomalacia, those of group 2b patients aluminium osteodystrophy. These data show a high prevalence of aluminium overload in Brazilian patients. Low-dose DFO therapy was safe, decreased bone pain, prevented fractures, and reduced stainable bone aluminium. Bone lesions only partially improved, suggesting that low phosphorus intake and/or plasma calcitriol concentrations may have prevented improvement of bone formation and mineralization. [ABSTRACT FROM PUBLISHER] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
